WCM Investment Management LLC Lowers Stock Position in Eli Lilly and Company $LLY

WCM Investment Management LLC decreased its stake in Eli Lilly and Company (NYSE:LLY) by 3.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,312 shares of the company’s stock after selling 624 shares during the period. WCM Investment Management LLC’s holdings in Eli Lilly and Company were worth $13,576,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its holdings in shares of Eli Lilly and Company by 3.3% in the first quarter. Dimensional Fund Advisors LP now owns 3,895,925 shares of the company’s stock worth $3,582,704,000 after buying an additional 124,352 shares during the period. Human Investing LLC increased its position in Eli Lilly and Company by 0.7% during the 1st quarter. Human Investing LLC now owns 2,324 shares of the company’s stock valued at $2,137,000 after purchasing an additional 17 shares during the period. Scarborough Advisors LLC bought a new position in Eli Lilly and Company in the first quarter worth about $674,000. Balefire LLC raised its holdings in Eli Lilly and Company by 11.8% in the first quarter. Balefire LLC now owns 2,087 shares of the company’s stock worth $1,920,000 after purchasing an additional 220 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.5% during the first quarter. Parallel Advisors LLC now owns 30,405 shares of the company’s stock valued at $27,966,000 after purchasing an additional 439 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,146.90 on Tuesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The company has a market cap of $1.08 trillion, a P/E ratio of 40.74, a P/E/G ratio of 1.48 and a beta of 0.51. The business’s 50 day moving average price is $1,122.49 and its 200-day moving average price is $1,036.98.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 34.55 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on LLY shares. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Royal Bank Of Canada raised their target price on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 8th. Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a report on Monday, July 6th. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Finally, Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,283.64.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor interest remains strong in Eli Lilly thanks to its leadership in the fast-growing weight-loss and GLP-1 drug market, which continues to support long-term growth expectations.
• Positive Sentiment: Articles highlighting a possible stock split suggest shares trading above $1,000 could make LLY more accessible to retail investors and keep demand elevated.
• Positive Sentiment: Erste Group Bank issued an optimistic earnings estimate for LLY, reinforcing confidence in the company’s strong profit outlook.
• Neutral Sentiment: Coverage describing Eli Lilly as a trending stock shows the name remains heavily watched, which can amplify moves but does not by itself change fundamentals.
• Neutral Sentiment: Several valuation-focused articles argue the stock looks expensive or fully valued after its massive multi-year rally, suggesting expectations are already high.
• Neutral Sentiment: News about Eli Lilly’s $3.8 billion psychedelic-medicine deal and commentary around the ATAI buyout are more about strategic expansion than immediate revenue impact.
• Negative Sentiment: Recent commentary that LLY may be fully valued, stretched, or expensive has likely added to profit-taking pressure after the stock’s strong advance.
• Negative Sentiment: One market recap noted Eli Lilly fell more than the broader market in the latest session, reflecting a weaker short-term trading tone.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.